Participant characteristics
Participants :	Treatment group		Comparison group 1		Comparison group 2 (N/A)
	N=		N=		N=
Age (mean, median, range, SD):	Mean: Median: Range: SD:		Mean: Median: Range: SD:		Mean: Median: Range: SD:
Gender of participants:      (numbers / %, etc)	Male N= Female N = Both N = Not clear		Male N= Female N = Both N = Not clear		Male N= Female N = Both N = Not clear
Relevant neurological conditions within groups :	1._______________ N=______ 2._______________ N=______ 3._______________N=______ 4._______________N=______		1._______________ N=______ 2._______________ N=______ 3._______________N=______ 4._______________N=______		1._______________ N=______ 2._______________ N=______ 3._______________N=______ 4._______________N=______
Can relevant neurological disease groups be extracted?	Yes No Unclear/to contact authors		Yes No Unclear/to contact authors		Yes No Unclear/to contact authors
Co‐morbidities within exclusion criteria present/ reported? (e.g. H&N Ca, tracheostomy, congenital neuro condition, oesophageal disease, structural abnormality)
Trial characteristics
		Treatment group		Comparison group 1		Comparison group 2 (N/A)
Interventions: a)     botulinum toxin injections b)    placebo intervention c)     dysphagia rehabilitation (describe nature & intensity) d)    other		a)b)c)d)		a)   b)   c)   d)		a)   b)   c)   d)
How was participant eligibility defined?
Type/brand of drug treatment(s) used?
Dosage of drug treatment?
Method used to identify injection site ?
Injection methods (i.e. transcutaneous or endoscopic?)
Site of injection?
Size and calibre of needle
Injection administered by:
Time points of measurement collected?
Time‐frames considered:                                                      Immediate change (e.g. within one week)                                     Medium change (1‐6 months)                                                            Long term change (>6 months)		Yes/ no/ unclear Yes/ no/ unclear Yes/ no/ unclear		Yes/ no/ unclear Yes/ no/ unclear Yes/ no/ unclear		Yes/ no/ unclear Yes/ no/ unclear Yes/ no/ unclear
Trial design (e.g. parallel / cross‐over*)